Properties
What is it?
International Nonproprietary Name - Natrii lactas+Sorbitolum+Na+Mg+K+Ca Pharmacological Group: Electrolyte and acid-base balance correcting agents Composition: Active substance: 1 ml of solution contains - Sorbitol 60.0 mg, Sodium lactate (calculated on 100% substance) 19.0 mg, Sodium chloride 6.0 mg, Calcium chloride dihydrate (calculated on calcium chloride) 0.1 mg, Potassium chloride 0.3 mg, Magnesium chloride hexahydrate (calculated on magnesium chloride) 0.2 mg; Excipient: Water for injection. Dosage Form: Solution for infusion. Main physicochemical properties: Clear colorless liquid; theoretical osmolarity – 891 mOsmol/L; pH 6.00-7.60; ionic composition: 1 L of preparation contains Na+ - 272.20 mmol, K+ - 4.02 mmol, Ca++ - 0.90 mmol, Mg++ - 2.10 mmol, Cl- - 112.69 mmol, Lac- – 169.55 mmol. Pharmacotherapeutic Group: Solutions affecting electrolyte balance. Electrolytes in combination with other drugs. Clinical Features: Indications For improving capillary blood circulation in the treatment and prevention of traumatic, surgical, hemolytic, toxic, and burn shock, in cases of acute blood loss, burns; infectious diseases accompanied by intoxication, exacerbation of chronic hepatitis; sepsis; in the preoperative and postoperative periods; for improving arterial and venous blood circulation for the prophylaxis of thrombosis, thrombophlebitis, endarteritis, Raynaud's disease. Contraindications Increased individual sensitivity to the components of the preparation. Reosorbilact is not used in alcoholism, as well as when large volumes of fluid administration are contraindicated (cerebral hemorrhage, thromboembolism, cardiovascular decompensation, arterial hypertension grade III, decompensated heart defects, terminal renal failure), dehydration, oliguria. Interactions with other medicinal products and other types of interactions Not used as a solvent-carrier for other medicinal products. Use during pregnancy and lactation There is no data on contraindications for use during pregnancy or lactation. Effect on the speed of reaction when driving vehicles or operating other mechanisms Since the preparation is used in inpatient settings, there is no information on such effects. Method of administration and dosage Reosorbilact is administered intravenously to adults by drip at a rate of 40-60 drops/min. If necessary, the preparation can be administered by infusion at a rate of 30 drops/min after a test dose. After administering 15 drops, the use of the preparation is stopped, and after 3 minutes, in the absence of a reaction, Reosorbilact is administered by infusion. In cases of traumatic, burn, postoperative, and hemolytic shock in adults, 600-1000 ml (10-15 ml/kg of patient's body weight) is administered once, and then repeatedly 600-1000 ml (10-15 ml/kg of patient's body weight), initially by infusion, then by drip. In chronic hepatitis in adults, 400 ml (6-7 ml/kg of body weight) is administered by drip. In cases of acute blood loss in adults, 1500-1800 ml (up to 25 ml/kg of body weight) is administered. In such cases, Reosorbilact® infusion is recommended to be carried out at the pre-hospital stage in a specialized ambulance. In the preoperative period and after various surgical interventions – 400 ml (6-7 ml/kg of body weight) by drip for 3-5 days. In obliterating vascular diseases – 8-10 ml/kg of body weight by drip, repeated every other day, up to 10 infusions per course of treatment. Children There is insufficient data on the experience of administration in children. Side effects Immune system disorders: anaphylactic reactions, angioneurotic edema, hyperthermia. Cardiac disorders: increased or decreased blood pressure, tachycardia, shortness of breath, acrocyanosis.